European Biotech Acquisition Corp. Units
EBACU
EBACU was delisted on the 2nd of March, 2023.
37 hedge funds and large institutions have $44.6M invested in European Biotech Acquisition Corp. Units in 2021 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 12 reducing their positions, and 29 closing their positions.
8% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 12
39% less funds holding
Funds holding: 61 → 37 (-24)
51% less capital invested
Capital invested by funds: $90.1M → $44.6M (-$45.5M)
83% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
+$2.1M |
| 2 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$1.15M |
| 3 |
MTCM
Mint Tower Capital Management
Amsterdam,
Netherlands
|
+$701K |
| 4 |
WC
Wealthspring Capital
West Harrison,
New York
|
+$370K |
| 5 |
D.E. Shaw & Co
New York
|
+$354K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$6.28M |
| 2 |
LA
Linden Advisors
New York
|
-$5.01M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$3.27M |
| 4 |
SCM
Suvretta Capital Management
New York
|
-$3.02M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$2.94M |
EBACU Hedge Fund Activity: Q2 2021 in Review
37 of the 5,768 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Units (EBACU) for Q2 2021, worth a combined $44.6M — down 51% from $90.1M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of EBACU and 5 opened new positions — a net loss of 24 holders — while 12 trimmed existing stakes and 11 added.
The largest buyer was First Trust Capital Management, opening a new position worth an estimated $2.1M. The largest seller was Citadel Advisors, exiting entirely with an estimated $6.28M sold.
- 37 institutional investors held European Biotech Acquisition Corp. Units (EBACU) as of Q2 2021, down from 61 in Q1 2021.
- Funds reported $44.6M of European Biotech Acquisition Corp. Units stock for Q2 2021, down 51% quarter-over-quarter.
- 5 funds opened new European Biotech Acquisition Corp. Units positions in Q2 2021 and 29 closed out, a net change of -24 holders.
- The largest European Biotech Acquisition Corp. Units buyer in Q2 2021 was First Trust Capital Management, an estimated $2.1M added.
- The largest European Biotech Acquisition Corp. Units seller in Q2 2021 was Citadel Advisors, an estimated $6.28M sold.
Based on aggregated 13F filings for Q2 2021.